SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
1-Year Return
17.43%
This Quarter Return
+2.5%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.28B
AUM Growth
-$181M
(-12%)
Cap. Flow
-$120M
Cap. Flow
% of AUM
-9.41%
Top 10 Holdings %
Top 10 Hldgs %
66.69%
Holding
88
New
13
Increased
13
Reduced
24
Closed
17
Top Buys
| 1 |
INZY
Inozyme Pharma
INZY
|
$53.3M |
| 2 |
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
|
$41.5M |
| 3 |
Amgen
AMGN
|
$28.4M |
| 4 |
NCNA
NuCana
NCNA
|
$17.2M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$14.9M |
Top Sells
| 1 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
$84.7M |
| 2 |
Gilead Sciences
GILD
|
$31M |
| 3 |
Coherus Oncology, Inc. Common Stock
CHRS
|
$27.5M |
| 4 |
Merck
MRK
|
$21.6M |
| 5 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$17.8M |
Sector Composition
| 1 | Healthcare | 98.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Coherus Oncology, Inc. Common Stock
CHRS
$151M
| $7.97M | 0.59% |
434,555
-1,498,666
| -78% | -$27.5M |
|
27
Cytokinetics
CYTK
$6.35B
| $7.56M | 0.56% |
349,296
+189,079
| +118% | +$4.09M |
|
28
Zymeworks
ZYME
$1.15B
| $7.08M | 0.52% |
151,902
-147,832
| -49% | -$6.89M |
|
29
Protagonist Therapeutics
PTGX
$3.78B
| $6.99M | 0.52% |
357,769
+31,705
| +10% | +$620K |
|
30
Kura Oncology
KURA
$713M
| $6.9M | 0.51% |
225,259
-385,720
| -63% | -$11.8M |
|
31
Supernus Pharmaceuticals
SUPN
$2.58B
| $6.88M | 0.51% |
330,295
-148,034
| -31% | -$3.08M |
|
32
TG Therapeutics
TGTX
$5.14B
| $6.7M | 0.5% |
250,401
-445,989
| -64% | -$11.9M |
|
|
XLRN
33
DELISTED
Acceleron Pharma Inc.
XLRN
| $6.7M | 0.5% |
59,546
-157,844
| -73% | -$17.8M |
|
|
RETA
34
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $6.69M | 0.5% |
68,615
+55,580
| +426% | +$5.42M |
|
|
MYOK
35
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $6.68M | 0.5% |
48,998
-62,812
| -56% | -$8.56M |
|
|
ARNA
36
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $6.59M | 0.49% |
88,150
+74,221
| +533% | +$5.55M |
|
37
Ovid Therapeutics
OVID
$83.9M
| $6.3M | 0.47% |
+1,097,621
| New | +$6.3M |
|
38
Mirum Pharmaceuticals
MIRM
$3.83B
| $6.19M | 0.46% |
321,252
-220,449
| -41% | -$4.25M |
|
|
AMRN
39
Amarin Corp
AMRN
$317M
| $4.93M | 0.37% |
58,529
-201,886
| -78% | -$17M |
|
40
Aclaris Therapeutics
ACRS
$227M
| $4.91M | 0.36% |
1,911,573
| – | – |
|
41
Puma Biotechnology
PBYI
$253M
| $4.8M | 0.36% |
475,982
-721,648
| -60% | -$7.28M |
|
|
CHMA
42
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $4.5M | 0.33% |
1,047,354
-582,867
| -36% | -$2.51M |
|
|
CCXI
43
DELISTED
ChemoCentryx, Inc.
CCXI
| $4.45M | 0.33% |
81,235
-15,681
| -16% | -$859K |
|
44
Kiniksa Pharmaceuticals
KNSA
$2.64B
| $4.24M | 0.31% |
276,628
-533,175
| -66% | -$8.17M |
|
|
AGTC
45
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $4.01M | 0.3% |
825,071
-320,183
| -28% | -$1.56M |
|
|
TCRR
46
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $3.52M | 0.26% |
+173,028
| New | +$3.52M |
|
47
Immatics
IMTX
$757M
| $3.45M | 0.26% |
+325,527
| New | +$3.45M |
|
48
Liquidia Corp
LQDA
$2.49B
| $3.34M | 0.25% |
679,400
-120,600
| -15% | -$593K |
|
49
BioCryst Pharmaceuticals
BCRX
$1.74B
| $2.73M | 0.2% |
793,054
-564,794
| -42% | -$1.94M |
|
50
Q32 Bio
QTTB
$21.3M
| $2.55M | 0.19% |
13,223
-5,920
| -31% | -$1.14M |
|